安慰剂
医学
内科学
依托泊苷
临床终点
化疗
胃肠病学
肺癌
卡铂
随机对照试验
顺铂
病理
替代医学
作者
Ying Cheng,J. Wang,Caicun Zhou,W. Yao,Q-M. Wang,Xuhong Min,Guo-Qiang Chen,Xingxiang Xu,X-Y. Li,Fei Xu,Yong Fang,Runxiang Yang,Guohua Yu,Yuping Gong,Jun Zhao,Yun Fan,Qingqing Liu,L. Cao,Xiaofei Li,K. Ma
标识
DOI:10.1016/j.iotech.2023.100556
摘要
In the phase 3 CAPSTONE-1 study, adebrelimab, a humanized IgG4 anti-PD-L1 monoclonal antibody, plus chemo as first-line treatment for ES-SCLC significantly improved overall survival (OS) vs placebo plus chemo. Here we reported updated outcomes ∼3 years after the enrollment of the last patient.
科研通智能强力驱动
Strongly Powered by AbleSci AI